Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer

PURPOSE: Zoledronic acid (ZA) or denosumab treatment reduces skeletal-related events; however, the safety of prolonged therapy has not been adequately studied. Here, we describe safety results of extended denosumab therapy in patients with bone metastases from the open-label extension phase of two p...

Descripción completa

Detalles Bibliográficos
Autores principales: Stopeck, Alison T., Fizazi, Karim, Body, Jean-Jacques, Brown, Janet E., Carducci, Michael, Diel, Ingo, Fujiwara, Yasuhiro, Martín, Miguel, Paterson, Alexander, Tonkin, Katia, Shore, Neal, Sieber, Paul, Kueppers, Frank, Karsh, Lawrence, Yardley, Denise, Wang, Huei, Maniar, Tapan, Arellano, Jorge, Braun, Ada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669370/
https://www.ncbi.nlm.nih.gov/pubmed/26335402
http://dx.doi.org/10.1007/s00520-015-2904-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4669370/
https://www.ncbi.nlm.nih.gov/pubmed/26335402
http://dx.doi.org/10.1007/s00520-015-2904-5

Ejemplares similares